NVO Jan 2024 80.000 call
| Previous close | 66.00 |
| Open | 66.00 |
| Bid | 74.00 |
| Ask | 79.00 |
| Strike | 80.00 |
| Expiry date | 2024-01-19 |
| Day's range | 66.00 - 66.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
- Globe Newswire
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial
Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg an
- Bloomberg
Obesity Drug Hit Makes Novo Nordisk More Valuable Than Nestle
(Bloomberg) -- It’s the Wegovy effect. Most Read from BloombergDeutsche Bank Drops in Selloff Citi Describes as IrrationalJack Dorsey’s Wealth Tumbles $526 Million After Hindenburg ShortUBS Sends Khan to Stem Credit Suisse’s Private Banker ExitsCredit Suisse, UBS Among Banks in DOJ Russia-Sanctions ProbeThe blockbuster weight-loss drug, a hit with Hollywood and Silicon Valley celebrities, has more than doubled the market value of Novo Nordisk A/S since 2021 and looks set to be a cash cow for the
- Zacks
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
